NCT04553692 2025-03-28
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
Phase 1 Terminated
IGM Biosciences, Inc.
Children's Oncology Group
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center